Suppr超能文献

屋尘螨维持期皮下免疫疗法诱导周期性免疫效应。

Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects.

作者信息

Chaoul Nada, Albanesi Marcello, Giliberti Lucia, Rossi Maria Pia, Nettis Eustachio, Di Bona Danilo, Caiaffa Maria Filomena, Macchia Luigi

机构信息

Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico di Bari, Bari, Italy.

Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico di Bari, Bari, Italy,

出版信息

Int Arch Allergy Immunol. 2019;179(1):37-42. doi: 10.1159/000496436. Epub 2019 Mar 28.

Abstract

BACKGROUND

Subcutaneous immunotherapy (SCIT) is an effective treatment of respiratory allergies including house dust mite (HDM) and Hymenoptera venom allergy. During the build-up phase, the allergen is administered weekly at increasing doses, while during the maintenance phase, it is administered at a fixed high dose every 4 weeks. Upon SCIT injection, the allergen is driven to the draining lymph nodes where it most likely induces an immune response. Immunologic changes are thus supposedly induced at each injection.

OBJECTIVES

It is now established that SCIT induces tolerance in the long term, but the precise underlying immunologic mechanisms remain unclear. Therefore, we wanted to analyze the immunologic changes induced in both innate and adaptive immune cells at each individual SCIT administration during the maintenance phase in HDM-allergic patients. More specifically, we wondered whether the changes in regulatory T cell (Treg) and IgE+ B cell percentages, which are observed at the end of a 3-year course of SCIT, already occurred during the maintenance phase and whether these possible changes were sustained.

METHODS

We enrolled 6 patients suffering from HDM allergic rhinitis and undergoing maintenance HDM SCIT for 18-24 months. The same SCIT extract was used for all patients. We collected blood samples at 5 time points: T1 (immediately before a given SCIT injection), T2 (9 days after T1), T3 (29 days after T1 and right before the successive administration), T4 (39 days after T1), and T5 (61 days after T1 and just before the next injection). Six non-allergic age-matched healthy individuals were used as controls. Using flow cytometry, we assessed the following cell subsets in peripheral blood mononuclear cells: CD4 and CD8 T cells, Tregs, B cells, IgE+ B cells, NK and NKT cells, and total and activated basophils.

RESULTS

HDM-allergic patients displayed increased percentages of CD4 and CD8 T cells and NK cells compared to healthy controls. In contrast, NKT cells, total B cells, and basophils were diminished. These differences were maintained throughout the time course and seemed to be independent of the periodical SCIT injections. On the contrary, Treg percentages were significantly reduced in all HDM-allergic patients at T1. However, they increased at T2 and T4 (9 days after each SCIT injection) but decreased again at T3 and T5, just before the next one, resulting in cyclic changes. IgE+ B cells were significantly increased at T1, even more increased after each administration (T2, T4), and went back to their initial levels at T3 and T5, also resulting in a cyclic pattern.

CONCLUSIONS

Our data suggest that during the SCIT maintenance phase, cycles of expansion/contraction of Tregs and IgE+ B cells occur at each SCIT injection. Therefore, the sustained induction of immune tolerance by SCIT, through the increase of Tregs, seems to depend on the periodical exposure to the allergen, at least during the early steady state.

摘要

背景

皮下免疫疗法(SCIT)是治疗包括屋尘螨(HDM)和膜翅目毒液过敏在内的呼吸道过敏的有效方法。在剂量递增阶段,每周递增剂量给予变应原,而在维持阶段,每4周给予固定高剂量。皮下免疫疗法注射后,变应原被输送至引流淋巴结,在那里很可能诱导免疫反应。因此,每次注射时推测会诱导免疫变化。

目的

现已确定皮下免疫疗法可长期诱导耐受性,但确切的潜在免疫机制仍不清楚。因此,我们想分析在HDM过敏患者维持阶段每次皮下免疫疗法给药时,先天免疫细胞和适应性免疫细胞中诱导的免疫变化。更具体地说,我们想知道在3年皮下免疫疗法疗程结束时观察到的调节性T细胞(Treg)和IgE+B细胞百分比变化是否在维持阶段就已发生,以及这些可能的变化是否持续存在。

方法

我们招募了6名患有HDM过敏性鼻炎并接受18 - 24个月HDM皮下免疫疗法维持治疗的患者。所有患者使用相同的皮下免疫疗法提取物。我们在5个时间点采集血样:T1(在给定的皮下免疫疗法注射前即刻)、T2(T1后9天)、T3(T1后29天且在连续给药前)T4(T1后39天)和T5(T1后61天且在下一次注射前)。6名年龄匹配的非过敏健康个体作为对照。使用流式细胞术,我们评估外周血单个核细胞中的以下细胞亚群:CD4和CD8 T细胞、Treg、B细胞、IgE+B细胞、NK和NKT细胞以及总嗜碱性粒细胞和活化嗜碱性粒细胞。

结果

与健康对照相比,HDM过敏患者的CD4和CD8 T细胞以及NK细胞百分比增加。相反,NKT细胞、总B细胞和嗜碱性粒细胞减少。这些差异在整个时间过程中保持,并且似乎与定期皮下免疫疗法注射无关。相反,所有HDM过敏患者在T1时Treg百分比显著降低。然而,它们在T2和T4(每次皮下免疫疗法注射后9天)增加,但在T3和T5(在下一次注射前)再次降低,导致周期性变化。IgE+B细胞在T1时显著增加,每次给药后(T2、T4)进一步增加,并在T3和T5时回到初始水平,也导致周期性模式。

结论

我们的数据表明,在皮下免疫疗法维持阶段,每次皮下免疫疗法注射时Treg和IgE+B细胞会出现扩增/收缩循环。因此,皮下免疫疗法通过增加Treg持续诱导免疫耐受似乎至少在早期稳态期间依赖于定期接触变应原。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验